Press release
Pulmonary Sarcoidosis Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies - Novartis (CMK 389), aTyr Pharma (ATYR1923), Actelion (Selexi
Pulmonary Sarcoidosis Pipeline
The Pulmonary Sarcoidosis therapeutic market is anticipated to evolve in the coming years owing to the rise in the number of incident cases of Pulmonary Sarcoidosis patients, the improvement in the diagnosis methodologies, incremental healthcare spending across the world, the intense research and development activities for new treatment and the launch of novel therapies. Some of the pipeline therapies in the Pulmonary Sarcoidosis therapeutics domain include CMK389 (Novartis Pharmaceuticals), ATYR1923 (aTyr Pharma), Selexipag (Actelion), Combination product: iNO or inhaled nitric oxide (Bellerophon) and others.
"Pulmonary Sarcoidosis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pulmonary Sarcoidosis Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Pulmonary Sarcoidosis Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Pulmonary Sarcoidosis Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Sarcoidosis treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pulmonary Sarcoidosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Pulmonary Sarcoidosis Therapeutics Domain:
https://www.delveinsight.com/report-store/pulmonary-sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Pulmonary Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/pulmonary-sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Pulmonary Sarcoidosis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Pulmonary Sarcoidosis. Currently, Corbus Pharmaceuticals is leading the therapeutics market with its Pulmonary Sarcoidosis drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Pulmonary Sarcoidosis Therapeutics Market Include:
- Novartis
- aTyr Pharma
- Relief Therapeutics
- AI Therapeutics
- SarcoMed USA
And many others
Pulmonary Sarcoidosis Drugs Covered in the Report Include:
- CMK 389: Novartis
- ATYR1923: aTyr Pharma
- Selexipag: Actelion
- Combination Product - iNO: Bellerophon
- Aviptadil: Relief Therapeutics
Further product details are provided in the report.
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Pulmonary Sarcoidosis Current Treatment Patterns
4. Pulmonary Sarcoidosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pulmonary Sarcoidosis Late-Stage Products (Phase-III)
7. Pulmonary Sarcoidosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pulmonary Sarcoidosis Discontinued Products
13. Pulmonary Sarcoidosis Product Profiles
14. Pulmonary Sarcoidosis Key Companies
15. Pulmonary Sarcoidosis Key Products
16. Dormant and Discontinued Products
17. Pulmonary Sarcoidosis Unmet Needs
18. Pulmonary Sarcoidosis Future Perspectives
19. Pulmonary Sarcoidosis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Sarcoidosis Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies - Novartis (CMK 389), aTyr Pharma (ATYR1923), Actelion (Selexi here
News-ID: 2943316 • Views: …
More Releases from DelveInsight Business Research
DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous …
DelveInsight, a global leader in healthcare research and analytics, announces the release of its in-depth Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology Assessment, providing unparalleled insights into the prevalence of cSCC among solid organ transplant recipients across 15 countries, including the United States, key European nations, and select countries in the Asia-Pacific (APAC) region.
The newly released assessment delivers country-specific epidemiological insights aimed at guiding strategic decision-making for pharmaceutical companies, healthcare providers,…
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (P …
DelveInsight's Market Size & Forecast Assessment Provides Data-Driven Insights for Patient-Centric Market Expansion Strategies
DelveInsight, a leading healthcare market research and consulting firm, has released an in-depth case study highlighting its latest assessment of the Patent Foramen Ovale (PFO) Device Market across the European Union. This strategic market intelligence report provides a holistic understanding of the patient population, device market size, competitor landscape, and reimbursement scenario, equipping medical device companies with…
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for …
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices Market is set for strong expansion, projected to grow at a CAGR of 6.35% from 2025 to 2032, according to recent industry findings. This growth is primarily fueled by the increasing global prevalence of COPD, escalating exposure to tobacco smoke and air pollution, expanding screening programs, and the rapid development of next-generation respiratory devices such as portable nebulizers and smart inhalers.
The global…
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CD40 pipeline constitutes key companies continuously working towards developing CD40 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"CD40 Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CD40 Market.
The CD40 Pipeline report embraces in-depth commercial and…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
